摘要:目的:探討胸腔穿刺手術時胸腔內注射尿激酶治療結核性胸膜炎胸膜肥厚、粘連的臨床療效。方法:將30例結核性胸膜炎包裹性胸腔積液、胸膜肥厚、粘連患者分為兩組:治療組15例,采用胸腔穿刺術抽胸水后胸腔注射尿激酶;對照組15例,采用常規胸腔穿刺抽胸水,胸腔內不注射尿激酶。比較兩組患者治療后胸膜肥厚、粘連程度。結果:治療組胸膜肥厚、粘連程度明顯減輕,與對照組差異有統計學意義(P<0.05)。結論:胸腔內注射尿激酶治療結核性胸膜炎胸膜肥厚、粘連療效肯定,操作簡便,值得推廣。
關鍵詞:結核性胸膜炎 尿激酶 胸膜粘連 肥厚
Chest cavity pours into urokinase treatment tubercular pleurisy curative effect observation
Li Xiang
Abstract:Objective:Discusses when the chest cavity puncture surgery in the chest cavity injects the urokinase treatment tubercular pleurisy pleural membrane plump,the adhesion clinical curative effect.Methods:Wraps 30 example tubercular pleurisy the chest cavity to accumulate plump the fluid,the pleural membrane,the adhesion patient divides into two groups:The treatment group 15 examples,after use the chest cavity puncture method to pull out the chest water the chest cavity injection urokinase;The control group 15 examples,use the conventional chest cavity puncture to pull out the chest water,in the chest cavity do not inject the urokinase.Treats the pleural membrane after two group of patients plump,the adhesion degree.Results:Treats the group pleural membrane plump,the adhesion degree reduces obviously,has statistics significance with the control group difference (P<0.05).Conclusion:In the chest cavity injects the urokinase treatment tubercular pleurisy pleural membrane plump,the adhesion curative effect affirmed that,the operation is simple,is worth promoting.
Keywords:Tubercular pleurisy Urokinase Pleural membrane adhesion Plump
【中圖分類號】R45【文獻標識碼】B 【文章編號】1008-1879(2010)11-0057-02
1 資料與方法
1.1 一般資料。本組患者30例,治療組和對照組各15例,采取隨機分組方法,其中治療組男8例,女7例,年齡21-57歲,平均年齡39歲;對照組男9例,女6例,年齡18~56歲,平均年齡37歲,兩組年齡、性別作統計學處理差異無顯著性。各組病例均已明確診斷為結核性胸膜炎,經胸水B超檢查提示:有少到中量胸腔積液,胸水中可見多條纖維條索影,全部已經形成包裹性胸腔積液、胸膜肥厚。
1.2 方法。兩組患者均給與2HREZ/4HR方案治療(H:異煙肼0.3g,利福平0.45g,乙胺丁醇0.75g,均1次/日,吡嗪酰胺0.5g,3次/日,)治療組抽盡胸水后胸腔注入尿激酶10萬U,24-72小時后復查胸水B超,有胸水時B超定位后繼續重復抽盡胸水后注射尿激酶10萬U。對照組根據B超定位行胸腔穿刺抽胸水,每周2-3次抽胸水,一周后根據B超結果判斷療效。
2 結果
治療組15例中胸水吸收、胸膜肥厚、粘連消失8例,明顯減輕5例,無變化2例,有效率為86.7%;對照組胸膜肥厚、粘連消失2例,明顯減